Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Bardet-Biedl syndrome in which the cause of the disease is a mutation in the TRIM32 gene.
Features include: Abnormality of the kidney, Polydactyly, Damage to the retina (retinopathy), and Hypogonadism and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 1 | Abnormality of the kidney |
Eyes |
TRIM32 function has not been fully characterized.
Bardet-Biedl syndrome 11 has limited evidence linking it to mutations in the TRIM32 gene on chromosome 9.
Genetic testing for TRIM32 is available. Testing is considered research-grade for diagnosis.
Biomarker and diagnostic research for Bardet-Biedl syndrome 11 has been reported in the published literature.
5 clinical trials registered, 4 recruiting. Interventions under study include other interventions and gene therapy. Pipeline includes 1 EARLY_PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT02329210](https://clinicaltrials.gov/study/NCT02329210) |
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 3:07 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Bardet-Biedl syndrome 11
1
Damage to the retina (retinopathy) |
Hormones | 1 | Hypogonadism |
Clinical Registry Investigating Bardet-Biedl Syndrome
— |
Marshfield Clinic Research Foundation |
RECRUITING |
[NCT04461444](https://clinicaltrials.gov/study/NCT04461444) | COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study | NA | University Hospital, Strasbourg, France | RECRUITING |
[NCT06239064](https://clinicaltrials.gov/study/NCT06239064) | Early Genetic Identification of Obesity | — | Rolfs Consulting und Verwaltungs-GmbH (RCV) | ACTIVE_NOT_RECRUITING |
[NCT02435940](https://clinicaltrials.gov/study/NCT02435940) | Inherited Retinal Degenerative Disease Registry | — | Foundation Fighting Blindness | RECRUITING |
[NCT07269665](https://clinicaltrials.gov/study/NCT07269665) | First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration | EARLY_PHASE1 | Axovia Therapeutics | RECRUITING |
23 publications have been identified in PubMed for Bardet-Biedl syndrome 11. Research spans Case Report / Case Series (39%), Epidemiology / Natural History (26%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 9 | 39% |
Disease patterns and progression | 6 | 26% |
Research summaries | 4 | 17% |
Testing and diagnosis research | 1 | 4% |
Clinical study results | 1 | 4% |
Laboratory research | 1 | 4% |
New treatment approaches | 1 | 4% |
Akhila P (2026). [PMID: 41611321](https://pubmed.ncbi.nlm.nih.gov/41611321/). *BMJ Case Rep*. [Case Report / Case Series]
Milheiro J (2026). [PMID: 41940113](https://pubmed.ncbi.nlm.nih.gov/41940113/). *Clin Nephrol Case Stud*. [Case Report / Case Series]
Hühne T (2026). [PMID: 40903014](https://pubmed.ncbi.nlm.nih.gov/40903014/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]
Argente J (2025). [PMID: 39549719](https://pubmed.ncbi.nlm.nih.gov/39549719/). *Lancet Diabetes Endocrinol*. [Clinical Trial Publication]
Zmysłowska-Polakowska E (2025). [PMID: 41304128](https://pubmed.ncbi.nlm.nih.gov/41304128/). *Microorganisms*. [Epidemiology / Natural History]
Li JM (2025). [PMID: 39618083](https://pubmed.ncbi.nlm.nih.gov/39618083/). *Ophthalmic Genet*. [Case Report / Case Series]
Demas N (2025). [PMID: 40877827](https://pubmed.ncbi.nlm.nih.gov/40877827/). *BMC Med Genomics*. [Diagnostic / Biomarker]
Mifsud F (2025). [PMID: 40897637](https://pubmed.ncbi.nlm.nih.gov/40897637/). *Obesity (Silver Spring)*. [Epidemiology / Natural History]
Ahmad Mian D (2025). [PMID: 40201460](https://pubmed.ncbi.nlm.nih.gov/40201460/). *AACE Clin Case Rep*. [Case Report / Case Series]
Zhang L (2025). [PMID: 40350403](https://pubmed.ncbi.nlm.nih.gov/40350403/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Case Report / Case Series]
AI-curated news mentioning Bardet-Biedl syndrome 11
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.